Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy

Trial Profile

Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Nov 2016

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Decompensated heart failure
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Tenax Therapeutics
  • Most Recent Events

    • 28 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top